Sexual transmission of murine papillomavirus (MmuPV1) in Mus musculus

Megan E Spurgeon, Paul F Lambert*

McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, United States

Abstract

Human papillomaviruses (HPVs) are the most common sexually transmitted infectious agents. Because of the species specificity of HPVs, study of their natural transmission in laboratory animals is not possible. The papillomavirus, MmuPV1, which infects laboratory mice (Mus musculus), can cause infections in the female cervicovaginal epithelium of immunocompetent mice that progress to cancer. Here, we provide evidence that MmuPV1 is sexually transmitted in unmanipulated, immunocompetent male and female mice. Female ‘donor’ mice experimentally infected with MmuPV1 in their lower reproductive tract were housed with unmanipulated male mice. The male mice were then transferred to cages holding ‘recipient’ female mice. One third of the female recipient mice acquired cervicovaginal infections. Prolonged infections were verified by histopathology and in situ hybridization analyses of both male and recipient female mice at the study endpoint. These findings indicate that MmuPV1 is a new model animal papillomavirus with which to study sexually transmission of papillomaviruses.

DOI: https://doi.org/10.7554/eLife.50056.001

Introduction

Human papillomaviruses (HPVs) are the most common sexually transmitted infection in the United States (Satterwhite et al., 2013), and oncogenic high-risk HPVs alone account for approximately 5% of cancers worldwide (zur Hausen, 2009). Despite the significant public health burden caused by these small DNA tumor viruses, research on papillomavirus sexual transmission has been severely limited due to the paucity of small animal preclinical models resulting from strict virus species-specific tropism. Mucosal tissues of the female reproductive tracts of rabbits (Harvey et al., 1998), multimammate rats (Nafz et al., 2007; Nafz et al., 2008), and rhesus macaques (Wood et al., 2007) are susceptible to rabbit oral papillomavirus (ROPV), mastomys coucha papillomavirus 2 (McPv2), and rhesus macaques papillomavirus (RhPV), respectively. However, natural transmission of a papillomavirus through sexual contact has only been reported in rhesus macaques (Ostrow et al., 1990). Unfortunately, cost and lack of suitable molecular biology tools and reagents for these models have generally deterred their broad scale use (Christensen et al., 2017; Uberoi and Lambert, 2017).

The recent discovery of a murine papillomavirus (MmuPV1 or MusPV1) (Ingle et al., 2011) alleviates many of these limitations, allowing the study of papillomavirus infection and disease in laboratory mice, which are tractable, genetically modifiable, and relatively affordable. MmuPV1 infects and causes disease at both cutaneous and mucosal sites of several common strains of laboratory mice (Uberoi and Lambert, 2017; Cladel et al., 2015; Cladel et al., 2017a; Cladel et al., 2013; Handisurya et al., 2014; Handisurya et al., 2013; Hu et al., 2015; Jiang et al., 2017; Joh et al., 2012; Sundberg et al., 2014; Wang et al., 2015). We recently published that MmuPV1 infection of the female reproductive tract causes neoplastic disease in immunocompetent FVB/N mice (Spurgeon et al., 2019). The severity of disease is exacerbated by treatment with estrogen (E2)
alone or in combination with ultraviolet B radiation (UVB), which induces prolonged systemic immunosuppression (Uberoi et al., 2016), leading to precancerous lesions and squamous cell carcinoma (SCC). Here, we describe application of our MmuPV1 infection cervicovaginal model to study MmuPV1 sexual transmission. We report natural papillomavirus sexual transmission in immunocompetent, unmanipulated male and female mice.

Results and discussion

Rationale and experimental design for MmuPV1 sexual transmission studies

By 4 months following experimental infection with MmuPV1 in their lower reproductive tract and treatment with E2 and UVB, immunocompetent FVB/N female mice develop high-grade precancerous cervicovaginal lesions and SCCs (Spurgeon et al., 2019). These lesions were associated with highly productive MmuPV1 infections throughout the cervicovaginal epithelia, as evidenced by strongly positive immunohistochemical staining for the major viral capsid protein L1 within the female reproductive tract (Spurgeon et al., 2019) (see also Figure 1A). This observation prompted us to test whether MmuPV1 can be sexually transmitted. Cohorts of female mice (referred to as ‘Donors’) that were either mock-infected or experimentally infected with MmuPV1+UV+E2 were held for 4 months (Figure 1B). The female Donors were then used to establish monogamous breeding pairs with uninfected male mice (referred to as ‘male Breeders’) and breeding allowed for at least 3 weeks. Male Breeders were then transferred into a cage with an uninfected female mouse (referred to as a ‘Recipient’) for at least 3 weeks. While the female Donors were treated with medroxyprogesterone acetate (Depo-Provera) and nonoxynol-9 to potentiate MmuPV1 infection (Spurgeon et al., 2019; Roberts et al., 2007), it is important to emphasize that none of the male Breeders were experimentally manipulated prior to or during matings and the female Recipients were not experimentally manipulated unless indicated below. We performed four separate transmission experiments summarized in Figure 1B and Table 1 using various conditions. In Experiments 1 and 2, breeding occurred for 3 weeks with both the Donor and Recipient, and Recipient female mice were treated with E2 for 2 months starting at 8 weeks post-breeding. In Experiment 3, a fraction of Recipients (n = 4) were pretreated with Depo-provera 5 days prior to breeding, and in Experiment 4, male Breeders remained with Donors and Recipients for 8 weeks each instead of 3 weeks. For Experiment 4, the Donors from Experiment 3 were used as the source of MmuPV1. All experiments
Figure 1. Rationale and experimental design for MmuPV1 sexual transmission studies. (A) A full-slide scan of a representative H and E-stained female reproductive tract from a Donor infected for 4 months with MmuPV1+UV+E2 with anatomical regions labeled. On the right, higher magnification images of the cervicovaginal fornix (inset) stained with H and E (left) or immunofluorescence for keratin (KRT; red) and MmuPV1 L1 capsid protein (L1); Figure 1 continued on next page.
were conducted with wild-type FVB/N mice, totaling 9 mock-infected and 22 MmuPV1 Donor-positive breeding pairs. Prior to housing with male Breeders, we first assessed whether the female Donors harbored infections in their reproductive tracts by performing cervicovaginal lavage (CVL). DNA recovered from the CVLs were subjected to PCR to detect MmuPV1 DNA and the host gene, p53, as a positive control (Figure 1C). All female Donors were found to have MmuPV1 infections based upon the CVL/PCR tests. This confirmed our previously published results that MmuPV1+UV+E2-infected mice efficiently establish infections that persist for at least 4 months (Spurgeon et al., 2019). Indeed the infections of these female Donors persisted for up to 10 months post-infection (Figure 1C).

Evidence for sexual transmission: Assessment of MmuPV1 infection status in female Recipient reproductive organs

To monitor for evidence for sexual transmission, we monitored the MmuPV1 infection status of the reproductive tracts of the female Recipient mice. CVL/PCR was performed on these mice starting approximately 3 weeks following introduction of the male Breeder mouse and approximately every month thereafter (Figure 2A). All female Recipient mice whose matings resulted in pregnancy were allowed to deliver offspring prior to their first CVL/PCR screen. Using this screening method, we identified 32% (n = 7/22) of female Recipient mice to harbor infections within their reproductive tracts (Figure 2B). These infections were observed across all four experiments (Table 1). Of the MmuPV1-positive female Recipient mice, 57% (n = 4/7) established prolonged MmuPV1 infections (MmuPV1 positive for at least 2 CVLs) while 43% (n = 3/7) had transient infections (MmuPV1 positive for only one CVL) (Figure 2B, Table 1). Prolonging the exposure of male Breeders to both the female Donors and female Recipients from 3 weeks to 8 weeks in Experiment 4 resulted in a higher percentage of MmuPV1-positive Recipients (50%; n = 3/6) than observed in Experiments 1 (33%; n = 1/3), 2 (33%; n = 2/6), or 3 and 3* (14%; n = 1/7). Preconditioning female recipient mice with Depo-Provera, a contraceptive drug, did not appear to influence susceptibility of mice to MmuPV1 infection (25% MmuPV1 positive: n = 1/4).

In a separate set of experiments, we determined that co-habitation of female mice experimentally infected with MmuPV1 in their reproductive tracts with uninfected female mice did not lead to transmission of MmuPV1 infections to the reproductive tracts of the latter mice based on negative CVL/PCR results (Figure 2C), consistent with the premise that the infections arising in reproductive tracts of Recipient females housed with male Breeders (Figure 2A and B) resulted from sexual activity between the males and females.

One obvious positive readout for sexual activity is pregnancy. Of the 7 Recipient females that acquired MmuPV1 infections in their reproductive tract, 6 became pregnant during the course of being housed with the male breeders (Table 1). The single Recipient female that did not become pregnant had been pre-treated with the contraceptive Depo-Provera (Mouse #16 in Experiment 3*). Pregnancy in the Donor females was less penetrant with 4 out of the 7 Donor female mice initially housed with these same male Breeders having become pregnant (Table 1). This lower penetrance likely reflects that the Donor Females were originally experimentally infected with MmuPV1 using a protocol that involves treatment with Depo-Provera, which can prevent estrus cycling for an extended period of time. We were interested in learning whether pups born to infected mums would acquire MmuPV1 infections. While our analysis was not exhaustive, we did not find evidence for MmuPV1 infections in the skin of several offspring of MmuPV1-positive Donor Females that we screened for E4 mRNA using in situ hybridization.
Table 1. Overview of MmuPV1 sexual transmission experiments and results

| Expt. | Experimental Conditions                                                                                                      | Treatment of DONOR Female | Infection status of DONOR pregnancy | Infection status of MALE BREEDER | Infection status of RECIPIENT female | RECIPIENT pregnancy (# if > 1) | # Positive CVL (total # of CVLs) in RECIPIENT Female |
|-------|------------------------------------------------------------------------------------------------------------------------------|----------------------------|------------------------------------|----------------------------------|-------------------------------------|-------------------------------|---------------------------------------------------|
| 1     | 3 weeks breeding; Recipients untreated prior to breeding, placed on E2 8 weeks after introduction of male.                   | No Virus #1               | Yes                                | Negative                         | Negative                            | Yes                           | 0 (4)                                             |
|       |                                                                                                                             | No Virus #2               | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | No Virus #3               | Yes                                | Negative                         | Negative                            | Yes                           | 0 (4)                                             |
| 3     | 3 weeks breeding; Recipients untreated prior to breeding.                                                                       | No Virus #4               | Yes                                | Negative                         | Negative                            | Yes                           | 0 (3)                                             |
|       |                                                                                                                             | No Virus #5               | Yes                                | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | No Virus #6               | Yes                                | Negative                         | Negative                            |                               |                                                   |
| 4     | Prolonged Donor and Recipient breeding with male (8 weeks). Recipients untreated prior to breeding.                           | No Virus #7               | Yes                                | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | No Virus #8               | Yes                                | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | No Virus #9               | Yes                                | Negative                         | Negative                            |                               |                                                   |
| 1     | 3 weeks breeding, Recipients untreated prior to breeding, placed on E2 8 weeks after introduction of male.                   | MmuPV1+UV+E2 #1           | No                                 | Positive                         | Negative                            | Yes                           | 0 (4)                                             |
|       |                                                                                                                             | MmuPV1+UV+E2 #2           | Yes                                | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #3           | Yes                                | Positive                         | Positive (Prolonged)                |                               |                                                   |
| 2     | 3 weeks breeding, Recipients untreated prior to breeding, placed on E2 8 weeks after introduction of male.                   | MmuPV1+UV+E2 #4           | No                                 | Negative                         | Negative                            | Yes                           | 0 (5)                                             |
|       |                                                                                                                             | MmuPV1+UV+E2 #5           | No                                 | Positive                         | Positive (Transient)               | Yes                           | 1 (5)                                             |
|       |                                                                                                                             | MmuPV1+UV+E2 #6           | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #7           | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #8           | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #9           | Yes                                | Negative                         | Positive (Transient)               |                               |                                                   |
| 3     | 3 weeks breeding; Recipients untreated prior to breeding, not treated with E2.                                                | MmuPV1+UV+E2 #10          | No                                 | Positive                         | Negative                            | Yes                           | 0 (3)                                             |
|       |                                                                                                                             | MmuPV1+UV+E2 #11          | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #12          | Yes                                | Negative                         | Negative                            |                               |                                                   |
| 3*    | 3 weeks breeding; female Recipients treated with Depo-Provera 5d prior to breeding, not treated with E2.                    | MmuPV1+UV+E2 #13          | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #14          | No                                 | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #15          | Yes                                | Negative                         | Negative                            |                               |                                                   |
|       |                                                                                                                             | MmuPV1+UV+E2 #16          | Yes                                | Negative                         | Positive (Prolonged)               |                               |                                                   |

Table 1 continued on next page
To confirm that the MmuPV1-positive PCR results from the CVLs reflect persistent infections of the cervical/vaginal epithelium, we performed endpoint histopathological and MmuPV1-specific in situ hybridization (RNAscope) analyses on the reproductive tract of a female Recipient mouse (Recipient #3), which was MmuPV1-positive at the endpoint by CVL/PCR (Figure 2A and D). RNAscope used probes to detect viral transcripts containing the E4 region because that region is present in most early and late transcripts (Xue et al., 2017). Several discrete regions of epithelia were positive for MmuPV1 viral transcripts. These regions correlated with histopathological signs of MmuPV1 infection (Spurgeon et al., 2019), including disorganization of the stratified epithelium, areas of hyperkeratinization, karyomegaly, perinuclear halos similar to koilocytes, and condensed chromatin. We also observed evidence for a productive viral infection as indicated by cells staining positively for the viral capsid protein L1 by immunofluorescence (Figure 2D), albeit at levels of detection that are much lower than that afforded by RNAscope-based detection of viral transcripts. The infected regions of epithelia were pathologically scored as having low-grade or mild dysplasia. This particular mouse was MmuPV1-positive by 6 weeks post-breeding, and treated for 2 months with estrogen starting at 8 weeks post-breeding. Our previous results indicate that neoplastic disease worsens in MmuPV1 and MmuPV1+E2-infected mice upon extended duration (4 or 6 months) (Spurgeon et al., 2019). It is therefore possible that MmuPV1-infected female Recipients may develop moderate to high-grade disease or even SCC if the infection is allowed to proceed for a longer period of time. We analyzed the reproductive tracts of additional Recipient female mice that were positive for MmuPV1 by CVL/PCR at the endpoint and found them to have sites of infections based upon MmuPV1 E4-specific in situ hybridization (data not shown). These results confirm that sexual transmission of MmuPV1 can lead to persistent infections in the absence of genetic or environmental manipulation.

**Male Breeders harbor infections in their reproductive organs**

Because many female Recipient mice contracted MmuPV1 infections of their reproductive organs after being housed with male Breeders (Figure 2), we evaluated the reproductive organs of the male Breeders for the presence of MmuPV1. Attempts to detect the MmuPV1 by lavage of the male genitalia were not successful (insufficient DNA was retrieved based upon an inability to detect mouse p53 DNA by PCR; data not shown). Therefore we resorted to in situ hybridization analysis of male reproductive organs obtained at the time of euthanasia. We identified several male Breeders with MmuPV1-positive foci of infection by RNAscope (Figure 3A). All foci of infections were detected in epithelia of the penis, including the glans epithelium, mump ridge groove, and prepuce (foreskin)/preputial space (Phillips et al., 2015; Rodriguez et al., 2011) (Figure 3B and C). Notably, many of these sites are anatomical locations infected by HPV in men (Giuliano et al., 2007). We also

| Expt. | Experimental Conditions | Treatment of DONOR Female | DONOR pregnancy | Treatment of MALE BREEDER | Infection status of MALE BREEDER | Infection status of RECIPIENT Female | RECIPIENT pregnancy | # Positive CVL (total # of CVLs) in RECIPIENT Female |
|-------|-------------------------|---------------------------|----------------|--------------------------|----------------------------------|-------------------------------------|-------------------|------------------------------------------------|
| 4     | Prolonged Donor and Recipient breeding with male (8 weeks). Recipients untreated prior to breeding, not treated with E2. | MmuPV1+UV +E2 #17        | No             | Negative                 | Negative                         | Yes (2)                             | 0 (4)             |
|       |                         | MmuPV1+UV +E2 #18        | No             | Negative                 | Negative                         | Yes (2)                             | 0 (4)             |
|       |                         | MmuPV1+UV +E2 #19        | Yes            | Negative                 | Positive (Prolonged)            | Yes (3)                             | 3 (4)             |
|       |                         | MmuPV1+UV +E2 #20        | No             | Negative                 | Negative                         | Yes                                 | 0 (4)             |
|       |                         | MmuPV1+UV +E2 #21        | No             | Negative                 | Positive (Transient)            | Yes (3)                             | 1 (4)             |
|       |                         | MmuPV1+UV +E2 #22        | No             | Negative                 | Positive (Prolonged)            | Yes (2)                             | 2 (4)             |

DOI: https://doi.org/10.7554/eLife.50056.004

Spurgeon and Lambert. eLife 2019;8:e50056. DOI: https://doi.org/10.7554/eLife.50056
Figure 2. Evidence for sexual transmission: Assessment of MmuPV1 infection status in female Recipient reproductive organs. (A) DNA was isolated from cervicovaginal lavage (CVL) samples collected from a group of representative Recipient female mice at three different occasions. The numerical mouse identifiers correspond to mice listed in Table 1. The three different CVL time points are as follows (time is listed in weeks following introduction to male Breeder): Mock Recipient mice #1–3 and Recipients #1–3 from Experiment 1 (CVL1: 6 weeks, CVL2: 13 weeks, CVL3: 17 weeks), Recipient mice #5, #8, and #9 from Experiment 2 (CVL1: 8 weeks, CVL2: 11 weeks, CVL3: 13 weeks), Recipient mouse #16 from Experiment 3* (CVL1: 3 weeks, CVL2: 4.5 weeks, CVL3: 9 weeks), and Recipient mice #19, #21, and #22 from Experiment 4 (CVL1: 4.5 weeks, CVL2: 7 weeks, CVL3: 9 weeks). DNA was analyzed by PCR for the MmuPV1 E2 gene (top) or for the p53 gene (bottom) to verify DNA presence/quality. (B) Incidence of MmuPV1 infection via sexual transmission in Recipient females as determined by CVL for MmuPV1 E2 gene. (C) Schematic of co-habitation study in which each co-housed pair consisted of an experimentally MmuPV1-infected female mouse and an uninfected female mouse. After 3 weeks of co-habitation, DNA isolated from cervicovaginal lavages was analyzed by PCR for the MmuPV1 E2 gene (top) or for the p53 gene (bottom) to verify DNA presence/quality. (D) Full-slide scans of the female reproductive tract harvested from Recipient Mouse #3 with a prolonged MmuPV1 infection as a result of sexual contact. Tissue is stained with H&E.
observed evidence for productive viral infections in the penis using L1 immunofluorescence (Figure 3B). Similar to our observation in the MmuPV1-positive Recipient females (Figure 2D), L1
was detected albeit at a lower level than that observed for E4 transcripts, which uses the sensitive RNAscope technology. Two of the male Breeders (Male #3 and Male #5) that had detectable MmuPV1 infections on their penis by the endpoint RNAscope analysis were associated with MmuPV1-positive female Recipients (Table 1). The other two males that had detectable MmuPV1 infections on their penis did not appear to have transmitted MmuPV1 to Recipient females, based upon CVL/PCR. It remains possible that they did transmit, but the infections in the female Recipients were transient in nature and not caught by the intermittent CVL/PCR tests. Other males that were negative for MmuPV1-infections based upon endpoint RNAscope analysis did transmit MmuPV1 to female Recipients, suggesting they either had transient infections or else their foci of persistent infections were missed by the RNAscope analysis, which is very possible as only one section per male mouse was subjected to in situ hybridization. Of the 4 MmuPV1-positive male Breeders we identified using in situ hybridization, only 1 Donor-Breeder mating resulted in pregnancy, whereas all 4 Breeder-Recipient matings resulted in pregnancies (Table 1).

Conclusions and significance
The data presented in this study provide strong evidence that MmuPV1 is sexually transmitted. MmuPV1 becomes the first model for studying sexual transmission of papillomaviruses in laboratory mice (Mus musculus). Our immediate goals are to use this natural sexual transmission model in immunocompetent mice to study the dynamics of sexual transmission, the role of host immunity, and methods for prevention and treatment.

Materials and methods

| Key resources table |
|---------------------|
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
| Strain, strain background | FVB/N | Taconic Biosciences | RRID:IMSR_TAC:fvb | Males (n = 31) Females (n = 31) |
| Strain, strain background | MmuPV1 | Joh et al., 2012 Uberoi et al., 2016 | GenBank: GU808564.1 | In-lab stock ‘AU 11/13’, pAU.4 |
| Antibody | Anti-MuPV1 L1 (rabbit polyclonal immune serum) | Chris Buck, NCI/NIH | | IF (1:5000) |
| Antibody | Anti-K14 (rabbit polyclonal) | BioLegend | Cat#905301; RRID:AB_2565048 | IF (1:1000) |
| Sequence-based reagent | MmuPV1_E2_1 | Hu et al., 2015 Cladel et al., 2017a Spurgeon et al., 2019 | PCR primers | GCCCGAAGACAACACCGCAG |
| Sequence-based reagent | MmuPV1_E2_2 | Hu et al., 2015 Cladel et al., 2017a Spurgeon et al., 2019 | PCR primers | CCTCCGCCTCGTCCCCAAATGG |
| Sequence-based reagent | p53-1 | Spurgeon et al., 2019 | PCR primers | TATACTCAGAGCCGGCCT |
| Sequence-based reagent | p53-2 | Spurgeon et al., 2019 | PCR primers | ACAGCGTGTTGGTACCTTAT |
| Sequence-based reagent | p53-3 | Spurgeon et al., 2019 | PCR primers | TCCTCGTGCTTACGGTAGT |
| Sequence-based reagent | MusPV-E4 | Xue et al., 2017 | RNAscope probe Cat#473281 |
| Commercial assay or kit | RNAscope 2.5 HD Detection Kit Brown | ACDBio | Cat# 322300 |
| Chemical compound, drug | Tyramide signal amplification (TSA)-related reagents | Online protocol: https://doi.org/10.17504/protocols.io.8cchsw |

Continued on next page
### Reagent type (species) or resource

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Chemical compound, drug          | medroxyprogesterone acetate | Amphastar Pharmaceuticals | Depo-Provera | 3 mg/animal, subcutaneous injection |
| Chemical compound, drug          | Nonoxynol-9 (4%) | Options Conceptrol | Cat#247149 | 50 µL/mouse, intravaginal |
| Chemical compound, drug          | Carboxyl methylcellulose (4%) | Sigma Aldrich | Cat# C4888 | 25 µL/mouse, intravaginal |
| Chemical compound, drug          | 17β-estradiol pellet, 0.05 mg/60 days | Innovative Research of America | Cat#SE-121 | 0.05 mg/60 days, subcutaneous pellet |
| Other                             | Hematoxylin QS | Vector | Cat#H-3404 | Counterstain |
| Other                             | Shandon Instant Hematoxylin | Thermo Fisher | Cat#6765015 | H and E stain |
| Other                             | Eosin       | Sigma Aldrich | Cat#E4382 | H and E stain |
| Other                             | DNase I     | Thermo Fisher Scientific | Cat#EN0521 | 20 units/sample |
| Other                             | RNase A     | Qiagen | Cat#1006657 | 500 µg/sample |
| Other                             | RNase T1    | Fermentas | Cat#EN0542 | 2000 units/sample |

### Animals

Immunocompetent, wild-type FVB/N mice (Taconic Biosciences; Albany, NY) mice were used in this study. All animal experiments were performed in full compliance with standards outlined in the ‘Guide for the Care and Use of Laboratory Animals’ by the Laboratory Animal Resources (LAR) as specified by the Animal Welfare Act (AWA) and Office of Laboratory Animal Welfare (OLAW) and approved by the Governing Board of the National Research Council (NRC). Mice were housed at McArdle Laboratory Animal Care Unit in strict accordance with guidelines approved by the Association for Assessment of Laboratory Animal Care (AALAC), at the University of Wisconsin Medical School. All protocols for animal work were approved by the University of Wisconsin Medical School Institutional Animal Care and Use Committee (IACUC, Protocol number: M005871).

### MmuPV1 cervicovaginal infection and treatment of Donor females

At 6–8 weeks of age, female virgin FVB/N mice were infected with MmuPV1 virus as described previously (Spurgeon et al., 2019). Briefly, mice were injected subcutaneously with 3 mg medroxyprogesterone acetate (Amphastar Pharmaceuticals, Rancho Cucamongo, CA) 4–7 days prior to MmuPV1 infection to induce diestrus. On the day of the infection, mice were pre-treated vaginally with 50 µL Contraceptol (Options, #247149) containing 4% nonoxynol-9 to induce chemical injury to the cervicovaginal epithelium. At 4 hr post-treatment with Contraceptol, mice were infected intravaginally with $10^8$ VGE (viral genome equivalents) MmuPV1 virions suspended in 25 µL 4% carboxyl methylcellulose (Sigma, #C4888). The MmuPV1 virus stock used for infection was generated by isolating virions from papillomas arising on infected FoxN1nu/nu mice. To treat mice with estrogen, a continuous-release estrogen (E2) tablet (17β-estradiol; 0.05 mg/60 days; Innovative Research of America, Sarasota, FL) was inserted subcutaneously in the shoulder fat pads of the dorsal skin. For those mice receiving estrogen, treatment began 5 days following MmuPV1 infection. A new tablet was inserted every 2 months as needed. Infection and estrogen treatment were performed while mice were anesthetized with 5% isoflurane. Animals were exposed to a single dose of UVB at 1000 mJ/cm². UVB was administered using a custom designed Research Irradiation Unit (Daavlin, Bryan, OH) with lamps controlled using Daavlin Flex Control Integrating Dosimeters.

### MmuPV1 sexual transmission

Donors were lavaged prior to breeding to confirm infection, and then introduced to male FVB/N to establish monogamous breeding pairs. After breeding with infected female Donor mice, the males were isolated for 2–5 days, then introduced to uninfected female Recipient mice. In all experiments
except Experiment 3, female recipient mice were 6–8 weeks old virgin mice that were not treated with depoprovera or nonoxynol-9. In Experiment 3, female Recipient mice were pre-treated with depoprovera 5 days prior to introduction of Male Breeder. Male breeding with female Recipient mice was allowed to proceed for 3 weeks in Experiments 1–3. In Experiment 4, breeding with female Donors and Recipients was allowed to proceed for 8 weeks.

**Vaginal lavage and detection of MmuPV1 by PCR**

The method for detecting MmuPV1 DNA by PCR in vaginal lavages was modified from that described in Hu et al. and Cladel et al. (Hu et al., 2015; Cladel et al., 2017b). Briefly, 25 μL of sterile PBS was introduced intravaginally with a pipette tip, triturating 4–5 times prior to retrieval using the pipetteman. The vaginal lavages were stored at −20˚C and DNA isolated using spin-columns (DNeasy Blood and Tissue Kit; Qiagen #69506, Hilden, Germany). Eluted DNA was analyzed by PCR using primers specific to the MmuPV1 E2 gene: MmuPV1_E2_1 (5'-GCCCGAAGACAACACCGCACG-3') and MmuPV1_E2_2 (5'-CCTCCGCCTCCTGCCCCAAATGG-3') and analyzed using agarose gel electrophoresis. The presence of DNA suitable for PCR amplification was verified by performing PCR for the p53 gene. The primers for the p53 gene were as follows: p53-1 (5’-TATACTGAGGCCGGCCT-3’), p53-2 (5’-ACAGCCTGGGTGTAACCTTAT-3’), and p53-3 (5’-TCCTCGTGCTTTACCCTATC-3’).

**Tissue procurement, Processing, and Histopathological Analysis**

Reproductive organs were harvested, fixed in 4% paraformaldehyde, and paraffin-embedded. Serial sections (5 μm) were cut and every 10th section was stained with H and E and evaluated by histopathology. The scoring system for worst stage of disease has been described previously (Spurgeon et al., 2019).

**MmuPV1 L1- cytokeratin dual immunofluorescence and RNA in situ hybridization**

A detailed protocol for detecting MmuPV1 L1 using a tyramide-based signal amplification (TSA) method is available at: dx.doi.org/10.17504/protocols.io.i8cchsw. MmuPV1 viral transcripts were detected using RNAscope 2.5 HD Assay-Brown (Advanced Cell Diagnostics, Newark, CA) according to manufacturer instructions with probes specific for MmuPV1 E4 (Catalog #473281) as described previously (Spurgeon et al., 2019; Xue et al., 2017). Tissue sections were treated following protease treatment and prior to probe hybridization with 20 units of DNase I (Thermo Fisher Scientific, #EN0521), or DNase I combined with 500 μg RNase A (Qiagen, #1006657) plus 2000 units RNase T1 (Fermentas, Waltham, MA, #EN0542) for 30 min at 40˚C. Slides were counterstained with hematoxylin before mounting and coverslipping.

**Image acquisition**

High resolution wide-field fluorescent images were acquired using Leica SP8 3X STED microscope (Xue et al., 2017) by means of a 20X objective lens (Specifications: HC PL APO 20x/0.75 CS2, Dry) LAS-X suite (version: 2.0.1). Full slide scans of tissues were performed using Aperio ScanScope XT Slide Scanner using 20x/0.75 Plan Apo objective. All other images were captured using a Zeiss AxioImager M2 microscope and AxioVision software version 4.8.2 (Jena, Germany).

**Acknowledgements**

We would like to thank Aayushi Uberoi for helpful and thoughtful discussions as we initiated this study. We thank members of RARC for providing animal care and the UWCCC Experimental Pathology Laboratory for processing tissue. We also thank Ella Ward-Shaw for embedding and cutting tissue, and for hematoxylin and eosin staining sections. We also thank Chris Buck (National Cancer Institute, Bethesda, MD) for providing us with antibody against MmuPV1 L1. We would also like to acknowledge Stephanie McGregor for consultation regarding pathology.

We thank the University of Wisconsin Translational Research Initiatives in Pathology laboratory, in part supported by the UW Department of Pathology and Laboratory Medicine and UWCCC grant.
Additional information

Funding

| Funder                  | Grant reference number | Author           |
|-------------------------|------------------------|------------------|
| National Institutes of Health | CA022443             | Paul F Lambert   |
| National Institutes of Health | CA210807             | Paul F Lambert   |
| National Institutes of Health | CA211246             | Megan E Spurgeon |
| National Institutes of Health | CA014520             | Paul F Lambert   |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Megan E Spurgeon, Paul F Lambert, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs
Megan E Spurgeon [https://orcid.org/0000-0002-9753-6615](https://orcid.org/0000-0002-9753-6615)
Paul F Lambert [https://orcid.org/0000-0001-7983-2755](https://orcid.org/0000-0001-7983-2755)

Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to an approved institutional animal care and use committee (IACUC) protocol (#M005871) of the University of Wisconsin School of Medicine and Public Health.

Decision letter and Author response
Decision letter [https://doi.org/10.7554/eLife.50056.009](https://doi.org/10.7554/eLife.50056.009)
Author response [https://doi.org/10.7554/eLife.50056.010](https://doi.org/10.7554/eLife.50056.010)

Additional files

Supplementary files
• Transparent reporting form
DOI: [https://doi.org/10.7554/eLife.50056.007](https://doi.org/10.7554/eLife.50056.007)

Data availability
All data generated and analyzed during this study are included in the manuscript and supporting files.

References
Christensen ND, Budgeon LR, Cladel NM, Hu J. 2017. Recent advances in preclinical model systems for papillomaviruses. Virus Research 231:108–118. DOI: [https://doi.org/10.1016/j.virusres.2016.12.004](https://doi.org/10.1016/j.virusres.2016.12.004), PMID: 27956145

Cladel NM, Budgeon LR, Cooper TK, Balogh KK, Hu J, Christensen ND. 2013. Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with mus Musculus papillomavirus 1 DNA and virus. Journal of Virology 87:9391–9395. DOI: [https://doi.org/10.1128/JVI.00777-13](https://doi.org/10.1128/JVI.00777-13), PMID: 23785210
Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Hu J, Christensen ND. 2015. A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections. PLOS ONE 10:e0120128. DOI: https://doi.org/10.1371/journal.pone.0120128, PMID: 25803616

Cladel NM, Budgeon LR, Cooper TK, Balogh KK, Christensen ND, Myers R, Majerciak V, Gotte D, Zheng ZM, Hu J. 2017a. Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy. Journal of General Virology 89:2520–2529. DOI: https://doi.org/10.1099/jgv.0.0009926, PMID: 28942760

Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Brendele SA, Christensen ND, Schell TD, Hu J. 2017b. Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to Cancer. Scientific Reports 7:16492. DOI: https://doi.org/10.1038/s41598-017-10894-4, PMID: 29208932

Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB. 2007. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. The Journal of Infectious Diseases 196:1146–1152. DOI: https://doi.org/10.1086/521629, PMID: 17955432

Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowry DR, Schiller JT. 2013. Characterization of mus Musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. Journal of Virology 87:13214–13225. DOI: https://doi.org/10.1128/JVI.02162-13, PMID: 24067981

Handisurya A, Day PM, Thompson CD, Bonelli M, Lowry DR, Schiller JT. 2014. Strain-specific properties and T cells regulate the susceptibility to papilloma induction by mus Musculus papillomavirus 1. PLOS Pathogens 10: e1004314. DOI: https://doi.org/10.1371/journal.ppat.1004314, PMID: 25121947

Harvey SB, Cladel NM, Budgeon LR, Walsh PA, Griffith JW, Lang CM, Christensen ND. 1998. Rabbit genital tissue is susceptible to infection by rabbit oral papillomavirus: an animal model for a genital tissue-targeting papillomavirus. Journal of Virology 72:5239–5244. PMID: 9573297

Hu J, Budgeon LR, Cladel NM, Balogh K, Myers R, Cooper TK, Christensen ND. 2015. Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model. Journal of General Virology 96:3554–3565. DOI: https://doi.org/10.1099/jgv.0.000295, PMID: 26399579

Ingle A, Ghim S, Joh J, Chepkoech I, Bennett Jenson A, Sundberg JP. 2011. Novel laboratory mouse papillomavirus (MusPV) infection. Veterinary Pathology 48:500–505. DOI: https://doi.org/10.1177/0300985810377186, PMID: 20685915

Jiang RT, Wang JW, Peng S, Huang T-C, Wang C, Cannella F, Chang Y-N, Viscidi RP, Best SRA, Hung C-F, Roden RBS. 2017. Spontaneous and Vaccine-Induced clearance of mus Musculus papillomavirus 1 infection. Journal of Virology 91. DOI: https://doi.org/10.1128/JVI.00699-17

Joh J, Jenson AB, Proctor M, Ingle A, Silva KA, Potter CS, Sundberg JP, Ghim SJ. 2012. Molecular diagnosis of a laboratory mouse papillomavirus (MusPV). Experimental and Molecular Pathology 93:416–421. DOI: https://doi.org/10.1016/j.yexmp.2012.07.001, PMID: 22796029

Nafz J, Köhler A, Ohnesorge M, Nindl I, Stockfleth E, Rösi F. 2007. Persistence of Mastomys natalensis natalensis papillomavirus in multiple organs identifies novel targets for infection. Journal of General Virology 88:2670–2678. DOI: https://doi.org/10.1099/vir.0.82955-0, PMID: 17872518

Nafz J, Schäfer K, Chen SF, Bravo IG, Ibberson M, Nindl I, Stockfleth E, Rösi F. 2008. A novel rodent papillomavirus isolated from anogenital lesions in its natural host. Virology 374:186–197. DOI: https://doi.org/10.1016/j.virol.2007.12.012, PMID: 18234262

Ostrow RS, McGlennen RC, Shaver MK, Kloster BE, Houser D, Faras AJ. 1990. A rhesus monkey model for sexual transmission of a papillomavirus isolated from a squamous cell carcinoma. PNAS 87:8170–8174. DOI: https://doi.org/10.1073/pnas.87.20.8170, PMID: 2172976

Phillips TR, Wright DK, Gradie PE, Johnston LA, Pask AJ. 2015. A comprehensive atlas of the adult mouse penis. Sexual Development 9:162–172. DOI: https://doi.org/10.1159/000431010, PMID: 26121556

Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowry DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nature Medicine 13:857–861. DOI: https://doi.org/10.1038/nm1598, PMID: 17603499

Rodriguez E, Weiss DA, Yang JH, Mhensenina J, Ferretti M, Cunha TJ, Barcellos D, Chan LY, Risbridger G, Cunha GR, Baskin LS. 2011. New insights on the morphology of adult mouse penis. Experimental and Molecular Pathology 58:2520–2529. DOI: https://doi.org/10.1016/j.yexmp.2012.07.001, PMID: 2172976

Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H. 2013. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sexually Transmitted Diseases 40:187–193. DOI: https://doi.org/10.1093/OLQ.0b013e31828bb553, PMID: 23403598

Spurgeon ME, Uberoi A, McGregor SM, Wei T, Ward-Shaw E, Lambert PF. 2019. A novel in vivo infection model to study papillomavirus-mediated disease of the female reproductive tract. mBio 10. DOI: https://doi.org/10.1128/mBio.00180-19, PMID: 30837335

Sundberg JP, Stearns TM, Joh J, Proctor M, Ingle A, Silva KA, Dadras SS, Jenson AB, Ghim SJ. 2014. Immune status, strain background, and anatomic site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic papillomas or endophytic trichoblastomas. PLOS ONE 9:e113582. DOI: https://doi.org/10.1371/journal.pone.0113582, PMID: 25474466

Uberoi A, Yoshida S, Frazer IH, Pitot HC, Lambert PF. 2016. Role of ultraviolet radiation in Papillomavirus-Induced disease. PLOS Pathogens 12:e1005664. DOI: https://doi.org/10.1371/journal.ppat.1005664, PMID: 27244228

Uberoi A, Lambert P. 2017. Rodent papillomaviruses. Viruses 9:362. DOI: https://doi.org/10.3390/v9120362
Wang JW, Jiang R, Peng S, Chang YN, Hung CF, Roden RB. 2015. Immunologic control of mus Musculus papillomavirus type 1. PLOS Pathogens 11:e1005243. DOI: https://doi.org/10.1371/journal.ppat.1005243, PMID: 26495972

Wood CE, Chen Z, Cline JM, Miller BE, Burk RD. 2007. Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. Journal of Virology 81:6339–6345. DOI: https://doi.org/10.1128/JVI.00233-07, PMID: 17428865

Xue XY, Majerciak V, Uberoi A, Kim BH, Gotte D, Chen X, Cam M, Lambert PF, Zheng ZM. 2017. The full transcription map of mouse papillomavirus type 1 (MmuPV1) in mouse wart tissues. PLOS Pathogens 13:e1006715. DOI: https://doi.org/10.1371/journal.ppat.1006715, PMID: 29176795

zur Hausen H. 2009. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260–265. DOI: https://doi.org/10.1016/j.virol.2008.11.046, PMID: 19135222